Navigating global market access requirements in a dynamic environment
As the COVID-19 crisis unfolds, the pharmaceutical and medical device industries are responding with new products, processes and solutions in record time. Many health technology appraisal (HTA) boards are prioritising these innovations, and COVID-19 has become the new work programme for many companies.
How will the changes brought about by the pandemic impact your existing pipeline of products? Will you need to adjust your existing HEOR evidence planning and timetables? Are there steps you can take to ensure that patients and providers will still have timely access to your pipeline of products?